Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07603856 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT07603856 is a Phase 2 study that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 39 participants.
The verdict
NCT07603856, a Phase 2 study, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
Current clinical trials testing the combination of immunotherapy with radiotherapy.
Interventions
- DRUG Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)
- DRUG Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments)
- RADIATION Ablative Hypofractionated Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2026-12-12 |
| Est. Completion | 2030-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07603856
The ClinicalTrials.gov registry entry for NCT07603856 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) is the first listed.
NCT07603856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07603856 about?
NCT07603856 is a clinical study titled "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer". Current clinical trials testing the combination of immunotherapy with radiotherapy.
What is the current status of trial NCT07603856?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2026-12-12. Estimated completion is 2030-06-25.
What interventions are being tested in trial NCT07603856?
The interventions under investigation include: Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) (DRUG), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments) (DRUG), Ablative Hypofractionated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT07603856?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.